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An important clinical feature of
invasive Staphylococcus aureus
disease is the tendency for
infection to persist or relapse
despite seemingly adequate
antibiotic therapy. One
mechanism by which this is
believed to occur is through the
emergence of antibiotic-resistant
small colony variants (SCVs) [1].
When SCVs are isolated from
individuals with S. aureus
infections, it is common to
simultaneously isolate the
antibiotic-sensitive parental strain
[1–4]. In this work we describe
how SCVs create an environment
that protects wild-type S. aureus
from the lethal effects of
aminoglycoside antibiotics.
We previously reported that
growth of S. aureus in broth
containing gentamicin resulted in
the emergence of SCVs [5].
However, after 24-hour
incubation the population
became dominated by wild-type
antibiotic-sensitive bacteria
(66.2% of the population; 95%
confidence interval, 32.8–99.5%).
Thus, the gentamicin-sensitive S.
aureus present in this
heterogeneous population were
able to multiply in the presence of
a lethal antibiotic. To examine
whether this resistance was
conferred by bacterial factors
present in the broth supernatant,
wild-type bacteria and SCVs were
grown in broth (from an OD650 of
0.3 to 1) and the supernatants
harvested. Fresh inocula of wild-
type gentamicin-sensitive S.
aureus were added either to fresh
broth, wild-type supernatant, or
SCV supernatant and growth
inhibition by gentamicin was
assayed (Figure 1A). Gentamicin
inhibited growth in broth and in
wild-type supernatant, but did
not inhibit growth in SCV
supernatant. 
Proteomic comparisons between
wild-type, SCV and revertant S.
aureus were used to examine how
SCVs altered their environment to
permit growth of the sensitive
variant in the presence of
gentamicin. Amino-terminal
sequencing of the differentially
expressed proteins revealed that
several of these are associated
with anaerobic respiration in other
organisms (Figure 2). Although the
changes in metabolism
accompanying a shift from aerobic
to anaerobic respiration are not
fully understood in S. aureus, these
data suggest that SCVs were
respiring anaerobically despite
growth in air. 
The downregulation of an
alkaline shock protein in SCVs
(Figure 2) suggests that the pH of
the environment may have been
changing. Uptake of gentamicin
by S. aureus is dependent upon
pH, in that lowering pH reduces
gentamicin uptake and efficacy
[6]. Changes in pH during bacterial
growth were therefore examined.
Fresh broth and the supernatant
of wild-type S. aureus grown
aerobically had a pH of 7, whereas
SCV supernatant and that of wild-
type S. aureus grown
anaerobically had a reduced pH of
6. We examined the effect of
readjusting the pH of these
supernatants, by the addition of
either HCl or NaOH, on growth
inhibition by gentamicin. All
culture broths at pH 6, regardless
of origin, supported the growth of
wild-type S. aureus in the
presence of gentamicin, while all
broths at pH 7 failed to do so
Figure 1.
(A) SCVs of S. aureus alter their environment to neutralize the growth-inhibiting effect
of gentamicin on wild-type antibiotic-sensitive bacteria. Gentamicin-sensitive wild-type
S. aureus were incubated in fresh broth, wild-type supernatant or SCV supernatant con-
taining gentamicin. The ability to grow in the presence of gentamicin is shown as a per-
centage of the growth of this strain in the absence of gentamicin. (B) SCVs of S. aureus
neutralize the effect of gentamicin by respiring anaerobically and lowering environ-
mental pH. The pH of fresh broth and supernatant of aerobically grown (Aer) wild-type
S. aureus is 7. In this environment gentamicin inhibits the growth of wild-type sensitive
S. aureus.  The pH of SCV supernatant and that of anaerobically grown (Anaer) wild-
type S. aureus is 6. In this environment gentamicin does not inhibit the growth of wild-
type sensitive S. aureus. By adjusting the pH of broth or Aer supernatant to 6, the
growth-inhibiting effect of gentamicin is neutralized. By adjusting the pH of SCV or
Anaer supernatant to 7, the growth inhibiting effect of gentamicin is restored. 
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(Figure 1B). This demonstrates
that the change in pH of the
environment inhibits the action of
gentamicin. These results strongly
suggest that the switching of a
subpopulation to anaerobically
respiring, gentamicin-resistant
SCVs, and their subsequent
growth, leads to pH changes
induced by fermentation that
protect wild-type gentamicin-
sensitive variants from the lethal
effects of the antibiotic. 
Social behaviour has been
documented to occur in the soil-
dwelling bacterium Myxococcus
xanthus [7,8], but such
coordinated and interactive
responses are less well defined
for pathogenic bacteria. It is
possible that the interaction
reported here between SCV and
wild-type S. aureus, conferring
population-wide resistance to
aminoglycoside antibiotics, is an
example of such behaviour. The
effect of pH on bacterial
physiology in vivo is not known,
but our findings may represent a
bacterial mechanism involved in
persistence and relapse of
localised S. aureus disease in
environments where buffering
may be less efficient than in the
systemic circulation. The benefit
of this dynamic for the bacterial
population as a whole is that it
circumvents the need to acquire
permanent resistance through
genetic mutation, a process that
is associated with a reduction in
intrinsic growth rates [9].
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Figure 2. Proteomic analysis of wild-type, SCV and revertant S. aureus.
Protein expression profile of whole cell extracts: wild type (lane 1), SCV (lane 2) and
revertant (REV) (lane 3). Protein bands differentially expressed in wild type and REV
versus SCV are indicated; protein identification is listed in the table.
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